News and Announcements
Kazia Therapeutics CEO Dr James Garner discusses ground-breaking Alliance study with Boardroom Media
- Published May 29, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Kazia Therapeutics CEO, Dr James Garner recently sat down with Boardroom Media in Sydney to discuss Kazia’s participation with the US National Cancer Institute backed Alliance for Clinical Trials in Oncology.
The National Cancer Institute is the leading cancer research organisation in the US, part of the US National Institute of Health.
The study, alongside US pharmaceutical giant Eli Lilly and biotechnology group Genentech, is for the treatment of cancer that has spread to the brain. Patients will be allocated to receive either GDC-0084 or drugs from Eli Lilly or Genentech, depending on the genetic profile of their tumour.
Importantly, initiation of this study brings the total number of ongoing clinical trials with GDC-0084 to four, each in different forms of brain cancer.
In the interview, Dr Garner discusses:
- Who the Alliance for Clinical Trials in Oncology is
- What the study will involve
- About brain metastases and the challenges involved in developing new treatments
- How the Alliance trial differs from Kazia’s own phase IIa study in GDC-0084
- How the Alliance study is an example of personalised medicine
Listen to the interview here.
You can also read the original ASX announcement on the study here.
About Kazia Therapeutics (ASX:KZA)
Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is developing cancer treatments for areas which there is a high unmet medical need. Our lead program, GDC-0084, a drug to treat glioblastoma multiforme, the most aggressive brain cancer, has completed phase 1 human trials with strong safety and early efficacy signals. It is currently being prepared for phase 2 human trials.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
